♦ Activies ♦
Gongwin Biopharm Holdings Co., Ltd. (hereinafter referred to as "Gongwin-KY", stock code: 6617) officially cooperates with National Taiwan University Hospital (NTUH) this month to start phase II human clinical trials on its primary liver cancer new drug PTS100; and the research project is focused on liver cancer patients who have failed arterial embolization therapy and do not meet targeted drug treatment criteria; approximately 30 cases are to be accepted, and it is expected to be completed by the end of 2019. Gongwin-ky stated that, since TFDA approved Phase II clinical trials, it has received support and affirmation from internal medicine related physicians of National Taiwan University Hospital. The company is confident that it will complete the clinical acceptance and the first-year follow-up of the subjects by the end of 2019, and then it will submit its phase III clinical trial application to TFDA.
►News Link：Gongwin-KY to Co-Operate with National Taiwan University Hospital on Liver Cancer New Drug PTS100 Phase II Human Clinical Trials
Medical Team(Front row) of National Taiwan University Hospital (NTUH)